The impact of COVID-19 on the routine management of patients with sickle cell disease (SCD) has been substantial and complex, as clinicians now need to ensure that patients receive appropriate care for SCD in balance with the challenges posed by the pandemic. In this article, Lanetta Bronté-Hall, MD, MPH, MSPH discusses the current data regarding the prevalence of COVID-19 among patients with SCD and provides guidance on best practice on the treatment and monitoring of SCD during the COVID-19 pandemic.